12345...1020...


What is nanomedicine? – Definition from WhatIs.com

Nanomedicine is the application of nanotechnology (the engineering of tiny machines) to the prevention and treatment of disease in the human body. This evolving discipline has the potential to dramatically change medical science.

Established and near-future nanomedicine applications include activity monitors, chemotherapy, pacemakers, biochips, OTC tests, insulin pumps, nebulizers, needleless injectors, hearing aids, medical flow sensors and blood pressure, glucose monitoring and drug delivery systems.

Here are a few examples of how nanomedicine could transform common medical procedures:

The most advanced nanomedicine involves the use of nanorobots as miniature surgeons. Such machines might repair damaged cells, or get inside cells and replace or assist damaged intracellular structures. At the extreme, nanomachines might replicate themselves, or correct genetic deficiencies by altering or replacing DNA (deoxyribonucleic acid) molecules.

See the rest here:

What is nanomedicine? – Definition from WhatIs.com

Nanomedicine Lab

Advanced Healthcare Materials, 2017, in press

Nature Communications, 2017, in press

Advanced Materials, 2017, in press

Nanoscale Horizons, 2017, in press

EMBO Molecular Medicine, 2017, 9(6): 733-736

Nature Nanotechnology, 2017, 12: 288290

Nanoscale, 2017, 9(14): 4642-4645

Nature Biomedical Engineering, 2017, 1: 0063

BioRxiv, posted online Jan. 18, 2017

Chem, 2017, 2(3): 322325

More here:

Nanomedicine Lab

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

August 15, 2017

Space travel can cause a lot of stress on the human body as the change in gravity, radiation and other factors creates a hostile environment. While much is known about how different parts of the body react in space, how lungs are affected by spaceflight has received little attention until now, say researchers at The University of Texas Medical Branch at Galveston and Houston Methodist Research Institute.

That will change, though, once their research project, which aims to grow lungs in space, reaches the International Space Station. UTMB and HMRI researchers say what they learn from the study could have real implications for astronauts, as well as those still on Earth, and could lead to future therapeutics.

“We know a lot about what happens in space to bones, muscle, the heart and the immune system, but nobody knows much about what happens to the lungs,” said Joan Nichols, a professor of Internal Medicine and Microbiology and Immunology, and associate director for research and operations for the Galveston National Laboratory at UTMB. “We know that there are some problems with lungs in space flight, but that hasn’t been closely looked into. We hope to find out how lung cells react to the change in gravity and the extreme space environment, and then that can help us protect astronauts in space, as well as the lungs of regular people here on Earth.”

This investigation represents the third of four collaborative projects currently active at the HMRI’s Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI, focuses on the investigation of nanotechnology-based strategies for medicine on Earth and in space. The research is supported by the Center for the Advancement of Science in Space, NASA and HMRI.

Scientists from UTMB and HMRI prepared bioreactor pouches that include lung progenitor and stem cells and pieces of lung scaffolding. The scaffolding is the collagen and elastin frame on which lung cells grow. Space X successfully launched the payload containing these pouches Aug. 14 on its 12th Commercial Resupply Services mission (CRS-12) from NASA’s Kennedy Space Center in Florida and is expected to arrive at the International Space Station Aug. 16. Once on the ISS, the cells are expected to grow on the scaffold in a retrofitted bioreactor.

Once the lung cells have returned to Earth, researchers will look for the development of fibrosis, the structure of the tissues and the response of immune cells, among other changes and damage that could occur to the lung cells. Lung injuries have been found to accelerate in space, and it is through close study of those cells that therapeutics hopefully could be developed.

Nichols and Dr. Joaquin Cortiella, a professor and director of the Lab of Tissue Engineering and Organ Regeneration at UTMB, have successfully grown lungs in their lab in Galveston, but now they will see if astronauts can do the same in zero gravity. Jason Sakamoto, affiliate professor and former co-chair of the Department of Nanomedicine at HMRI, has applied his novel organ decellularization process and nanotechnology-based delivery systems to support this overall lung regeneration effort.

“We have experience working with the Center for the Advancement of Science in Space to study our nanotechnologies in action on the International Space Station,” Grattoni said. “However, we are extremely excited to be a part of this clinical study, since it may play a pivotal role in how we approach future space travel in terms of preserving astronaut health. What we learn during this fundamental experiment could lead to science-fiction-like medical advancements, where organ regeneration becomes a reality in both deep space and here on Earth.”

Researchers at HMRI will take the results from UTMB and work on developing therapeutics that could help astronauts, as well as people on Earth.

“This exploration will provide fundamental insight for the collaborative development of cell-based therapies for autoimmune diseases, hormone deficiencies and other issues,” Grattoni said.

Explore further: Image: Testing astronauts’ lung health

The stellar views from the International Space Station are not the only things to take an astronaut’s breath away: devices like this are measuring astronauts’ breath to determine the health of their lungs. ESA astronaut …

Astronauts in space are valuable sources of scientific data. Researchers collect blood and urine samples to understand what effects living in weightlessness has on their bodies. For one experiment, investigators are interested …

A wide variety of research relies on growing cells in culture on Earth, but handling these cells is challenging. With better techniques, scientists hope to reduce loss of cells from culture media, create cultures in specific …

In a US presidential election that’s already been out of this world, the lone American astronaut in outer space has cast his vote, NASA said Monday.

Astronauts on Chinese space station Tiangong-2 greet ESA and Thomas Pesquet. This video was recorded inside the Chinese space station Tiangong-2 by astronauts Jing Haipeng and Chen Dong. The duo landed safely on Earth on …

Abba Zubair, M.D., Ph.D, believes that cells grown in the International Space Station (ISS) could help patients recover from a stroke, and that it may even be possible to generate human tissues and organs in space. He just …

The moon is likely very dry in its interior according to a new study from researchers at Scripps Institution of Oceanography at the University of California San Diego, published August 21, 2017 in the Proceedings of the National …

Mars is buffeted by turbulent snowstorms that occur only at night, according to a study released Monday that revises our understanding of Red Planet weather.

(Phys.org)By analyzing sets of data obtained by two X-ray space observatories, a team of German researchers has learned new insights into the nature of a solar-type star known as HD 209458. The new study, published Aug. …

The origin of binary stars has long been one of the central problems of astronomy. One of the main questions is how stellar mass affects the tendency to be multiple. There have been numerous studies of young stars in molecular …

A University of Oklahoma astrophysicist, Mukremin Kilic, and his team have discovered two detached, eclipsing double white dwarf binaries with orbital periods of 40 and 46 minutes, respectively. White dwarfs are the remnants …

While Monday’s total solar eclipse in the U.S. will be a once-in-a-lifetime sky show for millions, there’s a small group of people who have experienced it all before and they can’t get enough of it.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

Global Nanomedicine Market Research Report 2016

2016 Global Nanomedicine Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Nanomedicine industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

Download sample pages of this report: https://goo.gl/cBLFx6

The report firstly introduced the Nanomedicine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with: 1.) basic information; 2.) the Asia Nanomedicine industry; 3.) the North American Nanomedicine industry; 4.) the European Nanomedicine industry; 5.) market entry and investment feasibility; and 6.) the report conclusion.

Download sample pages of this report: https://goo.gl/cBLFx6

About Us:

Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

sales@kminsights.com

+1 (888) 278-7681

Visit link:

Global Nanomedicine Market Research Report 2016 satPRnews – satPRnews (press release)

Growth in Nanomedicine market-2017 trends, forecasts, analysis – satPRnews (press release)

The report firstly introduced the Nanomedicine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Download sample pages of this report: http://www.kminsights.com/request-sample-1892

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism.

The ongoing market trends of Nanomedicine market and the key factors impacting the growth prospects are elucidated. With increase in the trend, the factors affecting the trend are mentioned with perfect reasons. Top manufactures, price, revenue, market share are explained to give a depth of idea on the competitive side.

Each and every segment type and their sub types are well elaborated to give a better idea about this market during the forecast period of 2017respectively.

Download sample pages of this report: http://www.kminsights.com/request-sample-1892

About Us: Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact: sales@kminsights.com +1 (888) 278-7681

Originally posted here:

Growth in Nanomedicine market-2017 trends, forecasts, analysis – satPRnews (press release)

Preclinical research using 1 Tesla desktop MRI – News-Medical.net

An interview with Dr. Ichio Aoki, National Institutes for Quantum and Radiological Science and Technology.

I’m an MR imaging scientist in the preclinical field. I’m a team leader of the functional and molecular imaging team at the National Institute of Radiological Sciences (NIRS) in QST.

QST National Institutes for Quantum and Radiological Science and Technology is a new organization, which was launched in April 2016. QST has an imaging research section as well as a synchrotron, and nuclear fusion and high-power laser development sections.

My role at QST is to develop new magnetic resonance imaging technologies and contrast agents in the preclinical field.

Advanced Anatomical and Functional MRI from AZoNetwork on Vimeo.

The predominant theme of our research is to develop new in vivo imaging technologies that can recognize disease, evaluate the benefits of therapies, and discover new diagnostic biomarkers for preclinical applications.

We are working to develop advanced anatomical and functional MRI to reveal the brain function, and to develop functional contrast agents and nanoprobes that can visualize and characterize brain or tumor function, microstructure, and pathologies.

We are focusing on three research fields:

The reason for purchasing ICON is simple: that is for the development of contrast agents and the preclinical applications.

Almost seven years ago, we developed a nano-micelle-based gadolinium contrast agent with Prof. Kataoka. Although the contrast agent had excellent T1 reactivity at low-fields, it lost the contrast capability at 7Tesla.

Most of nanoparticle-based contrast agents have both high T1 and T2 reactivity. It means that low-field MRI can have better contrast. Therefore, we considered the 1Tesla MRI system.

There are two reasons for choosing the ICON system at NIRS. First, compatibility with the 7Tesla system. We have some data servers for preclinical MRI. The compatibility of the ICON data is important for us.

The second reason is to do with accuracy. The resonance frequency as a permanent magnet depends on the room temperature. ICON with ParaVision software can perform a frequency correction automatically.

In addition, quantitative mapping requires very high accuracy of measurements such as exact 180-degree RF power, special homogeneity, and sharp slicing. I confirmed that the ParaVision software has high accuracy, with anatomical imaging as well as with quantitative mapping.

High-field MRI has great signal-to-noise ratio, therefore, it has many advantages for micro-imaging, BOLD-based functional MRI, MR spectroscopy, and multinuclear imaging. Especially, 7Tesla MRI can provide unbelievable SNR for mouse brain imaging and tumor microstructure.

Nanoparticles in MRI For Improving Contrast Agents from AZoNetwork on Vimeo.

On the other hand, 1Tesla ICON system can provide high-contrast imaging with contrast agents and it is very easy to use. It is also important that the contrast is similar to that of clinical MRI scanners.

For example, with our manganese with calcium phosphate micelle, we used 7Tesla system for MR angiography and MR spectroscopy and ICON system for T1-weighted MRI. I believe that it is the optimal combination for the application.

I always discuss with many researchers and recommend optimal systems for their research purposes. Also, I talk with MR technologists Nitta-san and Ozawa-san and animal technologists Shibata-san and Hayashi-san for improvement of our research environment. I’d like to continue the study of functional and responsive contrast agent development such as manganese, nitroxyl radicals, and diagnostic agents using micelle, nanogels, and liposomes.

In addition, I have two plans for the near future. First, development of safer contrast agents. We believe that we can provide good contrast with the use of gadolinium.

Secondly, we call it a companion nano-imaging. Many kinds of nanomedicine have great advantages, particularly to reduce side effects. However, it is known that the drug accumulation into the focus have big dispersion. I believe that nanoparticle-based contrast agents can act as a predictive marker for nanomedicine, this will allow us to estimate the therapeutic effect before administration.

We will launch an alliance soon for next-generation MR imaging and contrast agent development. I hope that the alliance will provide an open innovation platform in Japan forboth academia and industry.

Team leader at the National Institute of Radiological Sciences (NIRS) April 2007 Present

Senior Scientist at the NIRS October 2006 March 2007.

Before that he was a visiting scientist and visiting associate at the NIRS between December 2005 and September 2006.

He spent 2 years as an Assistant Professor at the Department of Medical Informatics at the Meiji University of Oriental Medicine from April 2004 to March 2006.

Has been a visiting Fellow and special volunteer at the National Institutes of Health from April 2000 to July 2003.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Read the original here:

Preclinical research using 1 Tesla desktop MRI – News-Medical.net

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

August 15, 2017

Space travel can cause a lot of stress on the human body as the change in gravity, radiation and other factors creates a hostile environment. While much is known about how different parts of the body react in space, how lungs are affected by spaceflight has received little attention until now, say researchers at The University of Texas Medical Branch at Galveston and Houston Methodist Research Institute.

That will change, though, once their research project, which aims to grow lungs in space, reaches the International Space Station. UTMB and HMRI researchers say what they learn from the study could have real implications for astronauts, as well as those still on Earth, and could lead to future therapeutics.

“We know a lot about what happens in space to bones, muscle, the heart and the immune system, but nobody knows much about what happens to the lungs,” said Joan Nichols, a professor of Internal Medicine and Microbiology and Immunology, and associate director for research and operations for the Galveston National Laboratory at UTMB. “We know that there are some problems with lungs in space flight, but that hasn’t been closely looked into. We hope to find out how lung cells react to the change in gravity and the extreme space environment, and then that can help us protect astronauts in space, as well as the lungs of regular people here on Earth.”

This investigation represents the third of four collaborative projects currently active at the HMRI’s Center for Space Nanomedicine. The center, directed by Alessandro Grattoni, chairman and associate professor of the Department of Nanomedicine at HMRI, focuses on the investigation of nanotechnology-based strategies for medicine on Earth and in space. The research is supported by the Center for the Advancement of Science in Space, NASA and HMRI.

Scientists from UTMB and HMRI prepared bioreactor pouches that include lung progenitor and stem cells and pieces of lung scaffolding. The scaffolding is the collagen and elastin frame on which lung cells grow. Space X successfully launched the payload containing these pouches Aug. 14 on its 12th Commercial Resupply Services mission (CRS-12) from NASA’s Kennedy Space Center in Florida and is expected to arrive at the International Space Station Aug. 16. Once on the ISS, the cells are expected to grow on the scaffold in a retrofitted bioreactor.

Once the lung cells have returned to Earth, researchers will look for the development of fibrosis, the structure of the tissues and the response of immune cells, among other changes and damage that could occur to the lung cells. Lung injuries have been found to accelerate in space, and it is through close study of those cells that therapeutics hopefully could be developed.

Nichols and Dr. Joaquin Cortiella, a professor and director of the Lab of Tissue Engineering and Organ Regeneration at UTMB, have successfully grown lungs in their lab in Galveston, but now they will see if astronauts can do the same in zero gravity. Jason Sakamoto, affiliate professor and former co-chair of the Department of Nanomedicine at HMRI, has applied his novel organ decellularization process and nanotechnology-based delivery systems to support this overall lung regeneration effort.

“We have experience working with the Center for the Advancement of Science in Space to study our nanotechnologies in action on the International Space Station,” Grattoni said. “However, we are extremely excited to be a part of this clinical study, since it may play a pivotal role in how we approach future space travel in terms of preserving astronaut health. What we learn during this fundamental experiment could lead to science-fiction-like medical advancements, where organ regeneration becomes a reality in both deep space and here on Earth.”

Researchers at HMRI will take the results from UTMB and work on developing therapeutics that could help astronauts, as well as people on Earth.

“This exploration will provide fundamental insight for the collaborative development of cell-based therapies for autoimmune diseases, hormone deficiencies and other issues,” Grattoni said.

Explore further: Image: Testing astronauts’ lung health

The stellar views from the International Space Station are not the only things to take an astronaut’s breath away: devices like this are measuring astronauts’ breath to determine the health of their lungs. ESA astronaut …

Astronauts in space are valuable sources of scientific data. Researchers collect blood and urine samples to understand what effects living in weightlessness has on their bodies. For one experiment, investigators are interested …

A wide variety of research relies on growing cells in culture on Earth, but handling these cells is challenging. With better techniques, scientists hope to reduce loss of cells from culture media, create cultures in specific …

In a US presidential election that’s already been out of this world, the lone American astronaut in outer space has cast his vote, NASA said Monday.

Astronauts on Chinese space station Tiangong-2 greet ESA and Thomas Pesquet. This video was recorded inside the Chinese space station Tiangong-2 by astronauts Jing Haipeng and Chen Dong. The duo landed safely on Earth on …

Abba Zubair, M.D., Ph.D, believes that cells grown in the International Space Station (ISS) could help patients recover from a stroke, and that it may even be possible to generate human tissues and organs in space. He just …

Venus looks bland and featureless in visible light, but change the filter to ultraviolet, and Earth’s twin suddenly looks like a different planet. Dark and light areas stripe the sphere, indicating that something is absorbing …

The cosmic webthe distribution of matter on the largest scales in the universehas usually been defined through the distribution of galaxies. Now, a new study by a team of astronomers from France, Israel and Hawaii demonstrates …

Ten spacecraft, from ESA’s Venus Express to NASA’s Voyager-2, felt the effect of a solar eruption as it washed through the solar system while three other satellites watched, providing a unique perspective on this space weather …

Astronomers using Caltech’s Owens Valley Radio Observatory (OVRO) have found evidence for a bizarre lensing system in space, in which a large assemblage of stars is magnifying a much more distant galaxy containing a jet-spewing …

Even tiny dust particles have stories to tell especially when they come from outer space. Meteorites contain tiny amounts of what is popularly known as stardust, matter originating from dying stars. Such stardust is part …

Many exoplanets to be found by coming high-powered telescopes will probably be tidally lockedwith one side permanently facing their host staraccording to new research by astronomer Rory Barnes of the University of Washington.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more:

Lungs in space: research project could lead to new lung therapeutics – Phys.Org

siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

Early phase Northwestern Medicine research published in the journal Proceedings of the National Academy of Sciences has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer-based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor-initiating cells (BTICs).

BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy, explained the studys first author, Dou Yu, MD, PhD, research assistant professor of Neurological Surgery.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA) short sequences of RNA molecules that reduce the expression of specific cancer-promoting proteins directly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind, said Yu, who collaborated on the research with principal investigator Maciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patients tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissues but not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling, Yu said. Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits.

The strategy could also apply to other medical conditions related to the central nervous system not just brain tumors.

Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform, Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor-initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer, Lesniak summed up.

This article has been republished frommaterialsprovided by Northwestern University. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference

Dou Yu, Omar F. Khan, Mario L. Suv, Biqin Dong, Wojciech K. Panek, Ting Xiao, Meijing Wu, Yu Han, Atique U. Ahmed, Irina V. Balyasnikova, Hao F. Zhang, Cheng Sun, Robert Langer, Daniel G. Anderson, Maciej S. Lesniak. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proceedings of the National Academy of Sciences, 2017; 201701911 DOI: 10.1073/pnas.1701911114

Excerpt from:

siRNA Treatment for Brain Cancer Stops Tumor Growth in Mouse Model – Technology Networks

Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

For cancer patients, understanding the odds of a treatments success can be bewildering. The same drug, applied to the same type of cancer, might be fully successful on one persons tumour and do nothing for another one. Physicians are often unable to explain why.

Now, U of T Engineering researchers are beginning to understand one of the reasons.Abdullah Syed and Shrey Sindhwani, both PhD candidates,and their colleagues at the Institute of Biomaterials & Biomedical Engineering (IBBME) have created a technology to watch nanoparticles traveling into tumours revealing barriers that prevent their delivery to targets and the variability between cancers.

The biggest thing weve noticed is that nanoparticles face multiple challenges posed by the tumour itself on their way to cancer cells, says Sindhwani, an MD-PhD student in the Integrated Nanotechnology & Biomedical Sciences Laboratory of Professor Warren Chan (IBBME). Syed and Sindhwani co-published their findings online June 22, and on the cover of the Journal of the American Chemical Society. So the treatment might work for a while or worse, theres just enough of the drug for the cancer to develop resistance. This could be prevented if we can figure out the ways in which these barriers stop delivery and distribution of the drug throughout the cancer.

Tiny nanoparticles offer great hope for the treatment of cancer and other disease because of their potential to deliver drugs to targeted areas in the body, allowing more precise treatments with fewer side effects. But so far the technology hasnt lived up to its promise, due to delivery and penetration problems.

To dismantle this roadblock, the two graduate students searched for a way to better view the particles journey inside tumours. They discovered that the tough-to-see particles could be illuminated by scattering light off their surfaces.

The sensitivity of our imaging is about 1.4 millionfold higher, says Syed. First, we make the tissue transparent, then we use the signal coming from the particles to locate them. We shine a light on the particles and it scatters the light. We capture this scattering light to learn the precise location of the nanoparticles.

It was already understood that nanoparticles were failing to accumulate in tumours, thanks to a meta-analysis of the field done by Chans group. But the researchers have developed technologies to look at nanoparticle distribution in 3D, which provides a much fuller picture of how the particles are interacting with the rest of the tumour biology. The goal is to use this technology to gather knowledge for developing mathematical principles of nanoparticle distribution in cancer, similar to the way principles exist for understanding the function of the heart, says Syed.

And because each tumour is unique, this technology and knowledge base should help future scientists to understand the barriers to drug delivery on a personalized basis, and to develop custom treatments.

The next step is to understand what in cancers biology stops particles from fully penetrating tumours and then to develop ways to bypass cancers defences.

But the technology is also useful for diseases other than cancer. With the help of Professor Jennifer Gommerman, an researcher in the Department of Immunology who studies multiple sclerosis (MS), Syed and Sindhwani captured 3D images of lesions in a mouse model mimicking MS using nanoparticles.

This is going to be very valuable to anyone trying to understand disease or the organ system more deeply, says Sindhwani. And once we understand barriers that dont allow drugs to reach their disease site, we can start knocking them down and improving patient health adds Syed.

Original post:

Targeting tumours: IBBME researchers investigate biological barriers to nanomedicine delivery – U of T Engineering News

Medication for the unborn baby – Medical Xpress

August 8, 2017 Empas multicellular model, which is mimicking the placental barrier: a core of connective tissue cells, surrounded by trophoblast cells. Credit: Empa

An Empa team has succeeded in developing a new three-dimensional cell model of the human placental barrier. The “model organ” can quickly and reliably deliver new information on the intake of substances, such as nano-particles, by the placental barrier and on any possible toxic effects for the unborn child. This knowledge can also be used in the future for the development of new approaches to therapy during pregnancy.

During its development, the foetus is extremely susceptible to toxic substances. Even the tiniest doses can cause serious damage. In order to protect the unborn child,one of the tasks of the placenta is to act as a barrier to “filter out” harmful substances, while at the same time providing the foetus with the nutrients it needs. In recent years, however, evidence has increasingly suggested that the placental barrier is not 100 percent effective and that nano-particles are actually able to penetrate it.

Nano-particles are being used in ever more varied areas of our lives. They are used, for example, in sun creams to protect against sunburn; they are used in condiments to stop them getting lumpy; they are used to make outdoor clothing waterproof and they are likely to be used in the future to transport medicines to their rightful destinations in the body . “At the moment, pregnant women are not being exposed to problematic amounts of nano-particles, but in the future that could well happen due to the ever increasing use of these tiny particles,” suggests Tina Buerki of the “Department of Particles-Biology Interactions.”

In order to ensure the safe development of nano-particles in the most diverse areas of application, their absorption mechanism at the placental barrier and their effect on the mother, foetus and placenta itself must be looked at more closely. It is the size, charge, chemical composition and shape of the nano-particles that could have an influence on whether they actually penetrate the placental barrier and, if so, in what way they are able to do so. At the moment, however, this research is only in its infancy. Since the function and structure of the human placenta is unique, studies undertaken on pregnant mammals are problematic and often inconclusive. Traditional models of the human placental barrier are either very time consuming to construct, or are extremely simplified.

A 3-D model of the human placental barrier

Tests of this nature are best carried out on donated placentas that become available after childbirth by Caesarean section. The organs are connected as quickly as possible to a perfusion system and this ensures the tissue is provided with nutrients and oxygen. This model is, indeed, the most accurate, i.e. the most clinically relevant. It is, however, very technically demanding and, moreover,restricted to a perfusion time window of six to eight hours. Against that, such placentas can be used to reliably test the ability of any given nano-particle to penetrate the placental barrier. The model does not, however, yield any information on the mechanism used by the particle to penetrate this complex organ.

Researchers are therefore tending to fall back on the use of simple cell cultures and other modelling systems. An individual cell, possibly taken from the epithelium and subsequently cultivated and propagated in a petri dish, is perfectly suited to a whole range of different experiments. However, researchers cannot be certain that the cells in the petri dish will ultimately behave like those in the human body. The new model that the Empa team under Tina Buerki described in the scientific journal Nanoscale at the end of last year is, by contrast, three-dimensional and consists of more than one cell type. The cells exist in a tissue-like environment analogous to the placenta and can be experimented on for a longer period of time.

Golden test candidate

In order to create the model, the research team used the “hanging drop” technology developed by Insphero AG. This technology allows models to be created without “scaffolding,” which can hinder free access of the nano-particles to the cells in the subsequent transport tests. Rather than introducing the cells in a flat petri dish, a special device, in which the cells in the hanging drops combine to form spherical micro-tissue, is used. The resulting micro-tissue mimics the human placenta much more closely than cells cultivated on a “rigid” culture dish. Experiments can be carried out much more quickly using the 3-D model than with the real placenta and, significantly, on the most widely differing types of nano-particle. In this way, those nano-particles that show potentially toxic effects or demonstrate desirable transport behaviour can be efficiently pre-selected and the results verified using a real placenta.

The model has already proved itself in a second study, which the team has just published in the scientific journal Nanomedicine. Buerki’s team has come up with an absorption mechanism for gold particles that could be used in a range of medicinal applications. The Empa team looked at gold particles of various sizes and different surface modifications. In accordance with the results of other studies, the researchers discovered that small gold particles were able to penetrate the placental barrier more easily. In addition, fewer particles passed through the barrier if they were carrying polyethylene glycol (PEG) on their surfaces. These are chain-forming molecules that almost completely envelope the particles. PEG is often used in medicine to allow particles and other small structures to travel “incognito” in the body, thus preventing them being identified and removed by the immune system. “It therefore appears possible to control the movement of nano-particles through the placenta by means of their properties,” Buerki explains.

Medicines for pregnant women that do not harm the child

Empa’s research team is keen to further develop this 3-D model in the future. The team is hoping to augment the model using a dynamic component. This would, for example, mean introducing the micro-tissue in a micro-fluid system able to simulate blood circulation in the mother and child. Another approach would be to combine the model of the placenta with other models. “With the model of a foetus, for example,” Buerki suggests. In this way, complex organ interactions could also be incorporated and it would be possible, for example, to discover whether the placenta releases foetus-damaging substances as a reaction to certain nano-particles.

“With these studies, we are hoping to lay the foundations for the safe but nevertheless effective use of nano-medicines during pregnancy,” Buerki continued. If we understand the transport mechanisms of nano-materials through the placental barrier well enough, we believe we can develop new carrier systems for therapeutic agents that can be safely given to pregnant women. This is because many women are forced to take medicines even during pregnancy patients suffering from epilepsy or diabetes, for example, or patients that have contracted life-threatening infections. Nano-carriers must be chosen which are unable to penetrate the placental barrier. It is also possible, for example, to provide such carriers with “address labels,” which ensure that the medicine shuttle is transported to the correct organ i.e. to the diseased organ and is unable to penetrate the placenta. This would allow the medicine to be released first and foremost into the mother. Consequently, the amounts absorbed by the foetus or embryoand therefore the risk to the unborn child are significantly reduced.

Explore further: New placenta model could reveal how birth defect-causing infections cross from mom to baby

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More here:

Medication for the unborn baby – Medical Xpress

‘Nanomedicine’: Potentially revolutionary class of drugs are made-in … – CTV News

It’s rare for researchers to discover a new class of drugs, but a University of Calgary microbiology professor recently did so — by accident and now hopes to revolutionize autoimmune disease treatment.

In 2004, Dr. Pere Santamaria and his research lab team at the Cumming School of Medicine conducted an experiment to image a mouse pancreas, using nanoparticles coated in pancreatic proteins.

The work didnt go as planned.

Our experiment was a complete failure, he recently told CTV Calgary. We were actually quite depressed, frustrated about the outcome of that.

But the team was surprised to discover the nanoparticles had a major effect on the mice: resetting their immune systems.

The team realized that, by using nanoparticles, they can deliver disease-specific proteins to white blood cells, which will then go on to reprogram the cells to actively suppress the disease.

Whats more, the nanoparticles stop the disease without compromising the immune system, as current treatments often do.

Santamarias team believes nanomedicine drugs can be modified to treat all kinds of autoimmune and inflammatory diseases, including Type 1 diabetes, multiple sclerosis and rheumatoid arthritis.

Convinced that nanomedicine has the potential to disrupt the pharmaceutical industry, Santamaria founded a company to explore the possibilities, called Parvus Therapeutics Inc.

This past spring, Novartis, one of the worlds largest pharmaceutical companies, entered into a license and collaboration agreement with Parvus to fund the process of developing nanomedicine.

Under the terms of the agreement, Parvus will receive research funding to support its clinical activities, while Novartis receives worldwide rights to use Parvus technology to develop and commercialize products for the treatment of type 1 diabetes.

Its a good partnership, Santamaria said in a University of Calgary announcement. Bringing a drug to market requires science as well as money.

Santamaria cant say how long it might be before nanomedicine can be used to create human therapies, but he says everyone involved is working aggressively to make it happen.

With a report from CTV Calgarys Kevin Fleming

See the article here:

‘Nanomedicine’: Potentially revolutionary class of drugs are made-in … – CTV News

UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News

When Dr. Pere Santamaria arrived in Calgary in 1992 to join the Cumming School of Medicine, he never could have imagined he would make a groundbreaking discovery that would lead to a spinoff company. When I arrived, I found out that the grant money I was expecting hadnt come through, says Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases and member of the Snyder Institute for Chronic Diseases. So I had an empty lab with no research assistants and no salary. I had to beg my supervisor to give me $10,000 to start my research.

Despite the rocky start, Santamaria has achieved something many scientists dream of making a discovery that has practical applications for health care. Santamarias discovery revolves around the use of nanoparticles coated in proteins to treat autoimmune and inflammatory disorders.

They can be modified for different diseases, such as Type 1 diabetes, multiple sclerosis and rheumatoid arthritis without compromising the entire immune system, Santamaria explains. Instead, they basically work to reset the immune system.

Nanomedicines unique mechanism has the potential to disrupt the pharmaceutical industry entirely. Developing a new class of drugs is rare. With the assistance of Innovate Calgary, Santamaria started a company, Parvus Therapeutics Inc., to represent the technology and explore ways of bringing it to market. Announced in April 2017, Parvus entered into an exclusive deal with the Swiss pharma giant Novartis, hopefully leading to the development and commercialization of Parvuss nanomedicine to treat Type 1 diabetes.

Its a good partnership, Santamaria says. Bringing a drug to market requires science as well as money.

Supporting commercialization should be a top priority for all research, he continues. Our biggest responsibility is to the patients and making sure they have access to the medicine they need. With that in mind, Santamaria shares his insight for other researchers who may be interested in bringing their discoveries from the lab bench to the market.

If youre interested in investigating spin-out opportunities, get in touch with Innovate Calgary, which offers mentors, coaching, business skill development programs, intellectual property services and other back-office support.

Throughout the years, Santamarias work has been funded by numerous organizations, including Diabetes Canada, the Juvenile Diabetes Research Foundation, the Canadian Institutes of Health Research (CIHR) and the Diabetes Association, Foothills.He is a member of the Snyder Institute and associate member of the Hotchkiss Brain Institute.Santamaria named his company Parvus from the Greek word meaning small.

View post:

UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News

‘Blazing the trail’: University of Calgary research could lead to cures … – CBC.ca

Researchers at the University of Calgary say their work in the field of “nanomedicine”could lead to cures for Type 1 diabetes, multiple sclerosis and many more diseases.

Dr. Pere Santamaria said the process involves “nanoparticles” thousands of times smaller than a typicalhuman cell that could be used to stop the body from attacking itself.

That, he said, could potentially lead to cures for autoimmunedisorders.

“There are no drugs that can do that today,”said Santamaria, aprofessor ofimmunology at the University of Calgary.

“Other drugs that are being used to treat chronic inflammatory disorders impair the ability of the immune system to do its job, so there are secondary effects and longterm complications our drugs don’t do that.”

Pharmaceutical company Novartis has partnered with Santamaria’s own company, Parvus Therapeutics, to work on developing the nanomedicines and take the drugs to market.

Now with support and funding, Santamariasaid the new drug”has the potential to revolutionizemedicine” if the drugs pass clinical testing.

Santamariasaid autoimmune disordersarecaused by white blood cells attacking the tissues in a person’sown body.

Pharmaceutical company Novartis has partnered with Dr. Santamaria’s Parvus Therapeutics to work on developing nanomedicines to cure autoimmune disorders and take the drugs to market. (CBC)

Type 1 diabetesis treatable with insulin, but there is no cure. It’s the same for many other diseases.

“Our drugs aim to resolve the inflammation of the tissue, the attack of the tissue, and resolve that process altogether,” Santamaria said.

He said the nanoparticles could halt disorders without impairing the rest of the immune system.

“So we can reset the immune system to its steady state that means the healthy state without impairing the ability of our immune system to protect us against infections and cancer,”Santamariasaid.

Santamaria said the nanoparticleswere discovered during an experiment years ago, and the initialtestresults”made nosensewhatsoever.” Since that day, the nanomedicines havebeen in development and he credits the progress to curiosity.

“We almost shoved them under the rug,” Santamaria said.”We didn’t do that. Fortunately, we were pursued wth curiosity of researching.”

Santamaria said the process of taking a discovery from the research laboratory to the marketplace is enormously complex and the drug has yet to go through preclinical trials.

Because nanomedicine is such a new field of research, there is no firm timeline on when the medicinescould be available if they pass human trials.

“Our nanomedicineis a new class of drug … so we’re basically blazing the trail,” Santamaria said.

“We hope that we can carry that torch and be an example for all the investigators that might follow suit, that may run into discoveries such as the ones that we’ve made and hopefully they can follow in our footsteps.”

Link:

‘Blazing the trail’: University of Calgary research could lead to cures … – CBC.ca

Application of Nanomaterials in the Field of Medicine – Medical News Bulletin

There has been a growing interest in the different applications of nanomaterials in the field of medicine. An article published in Nanomedicine: Nanotechnology, Biology, and Medicine showed the ways in which Laponite, a synthetic clay made of nanomaterials, can be of use in clinical practice.

Current advances in technology have provided many opportunities to develop new devices that improve the practice of medicine. There has been a growing interest in the different applications of nanomaterials in the field of medicine.

An article published in Nanomedicine: Nanotechnology, Biology, and Medicine reviewed Laponite, a non-toxic synthetic clay composed of nanomaterials which has different uses in the field of medicine. Laponite can be used in drug delivery systems, as the synthetic clay protects substances from degradation in physiologic environments. Different experiments show that Laponite is effective not only in protecting drugs from degradation, but also in transporting and releasing drugs into the body. The degradation of Laponite in the physiologic environment also releases products which have biological roles, especially in bone formation.

Laponite has been shown to induce osteogenic differentiation of cells in the absence of other factors which are known to promote differentiation and cell growth. The application of nanomaterials in bioimaging has also been studied. In one experiment, Laponite was incorporated with gadolinum, a dye used in magnetic resonance imaging (MRI), resulting in brighter images and prolonged contrast enhancement for 1 hour post-injection. Laponite has also proven to be of use in the field of regenerative medicine and tissue engineering. This synthetic clay can elicit specific biologic responses, act as a carrier for biochemical factors, and improve the mechanical properties of scaffolds used for tissue growth.

In summary, nanomaterials and synthetic clays such as Laponite have many applications in the field of medicine. Although current published literature state no toxic effects on the human body, further studies are needed to assess safety before it can be applied to clinical practice.

Written By:Karla Sevilla

Add to Flipboard Magazine.

The rest is here:

Application of Nanomaterials in the Field of Medicine – Medical News Bulletin

Cancer survivor becomes a cancer fighter at a Philly start-up – Philly.com

What Debra Travers really wanted to be was a marine biologist, until I found out Jacques Cousteau wasnt hiring.

How she wound up as chief executive of PolyAurum LLC, a Philadelphia start-up developing biodegradable gold nanoparticles for treating cancerous tumors, involved a professional journey of more than 30 years in pharmaceutical and diagnostics industries, and a personal battle with the disease shes now in business to defeat.

After determining that studying sea creatures was not a viable career choice, Travers a military kid from all over switched her major at Cedar Crest College in Allentown to medical technology. She graduated in 1979, then worked for three years in a hospital laboratory until she concluded she didnt like shift work and could do more.

What followed was an impressive career progression: Travers started as a chemistry technician at DuPont Biomedical Products Division, advancing to executive positions in marketing and product development at Centocor, GlaxoSmithKline, Endo Pharmaceuticals, and IMS Health.

Much of that work involved bringing new products through the long development and regulation-heavy process from concept to launch, with experience in therapeutic areas including oncology, urology, pain medicine, cardiology, and rheumatology. In an industry of specialty silos, Travers developed a uniquely blended expertise in marketing and R&D.

It was on March 23, 2006, that her health-care vocation turned personal: Travers, then a 50-year-old mother of two, was diagnosed with breast cancer.

An oncologist recommended a double mastectomy, removal of both ovaries, and chemotherapy. The tearful pleadings of her daughter, Kelly, then 18 I need you here when I graduate college, when I get married, when I have kids persuaded Travers to follow that recommendation.

She returned to work at Endo for seven more years, as a director in project management, before being laid off in June 2013, one month before her daughters wedding. The break gave Travers time to concentrate on the big event and to start to think what Id like to do when I grow up.

That process would lead her in late 2015 to PolyAurum, a start-up spun out of the University of Pennsylvania.

I became a CEO and a grandmother in the same year, said Travers, now 61, chuckling during a recent interview at the Pennovation Center incubator in West Philadelphia. From there, her home in Delaware, and the sites of pitch opportunities with investors, she is working to raise $1.3 million in seed funding by early in the fourth quarter, to help get PolyAurum closer to clinical trials on humans.

So far, research and testing funded through $4 million in grants to the university has been limited to mice with tumors. It has shown that gold nanocrystals less than five millimeters in diameter greatly enhance the effectiveness of radiation on tumors without increasing harm to healthy surrounding tissue, said Jay Dorsey, an associate professor and radiation oncologist at Penn and one of four university faculty who developed the technology.

The effectiveness of metals in improving a tumors ability to absorb radiation has long been known, Dorsey said. But one of the stumbling blocks to incorporating gold nanoparticles in such therapeutics is that the metal is not eliminated from the body well, posing serious problems to vital organs such as the liver and spleen.

Penns David Cormode, a professor of radiology, and Andrew Tsourkas, a professor of bioengineering, have worked to make gold more biocompatible, resulting in PolyAurums current technology, Dorsey said. The gold nanocrystals are contained in a biodegradable polymer that allows enough metal to collect in a tumor. The polymer then breaks down, releasing the gold for excretion from the body so that it does not build up in key organs.

The companys name is a combination of those two essential ingredients: Poly, derived from polymer, and Aurum, the Latin word for gold.

Explaining all that, and the potential that PolyAurums founders see for extending and saving lives, is the message Travers now is in charge of disseminating the part of the critical path to commercialization that is not the strength of most researchers toiling in laboratories.

She knows what the founders dont know it just makes a perfect match, said Michael Dishowitz, portfolio manager at PCI Ventures, an arm of Penn that helps university start-ups find investors, recruit management, and get to market.

Since its formation about eight years ago, PCI has helped more than 150 companies secure more than $100 million in funding, said Dishowitz, who has a doctoratein bioengineering from Penn and spent several years studying the impact of cell-signaling pathways on orthopedic injury.

While calling PolyAurums technology cool and very transformative for treatment, Dishowitz also delivered a dose of reality about the rigors ahead, as health-care start-ups must navigate a course with no guarantees their products will lead to actual clinical implementation.

PolyAurum is one of 13 companies that entered Philadelphia Media Networks second annual Stellar StartUps competition in the health-care/life sciences category. A total of nine categories drew 88 applicants. The winners will be announced Sept. 12 at an event at the Franklin Institutes Fels Planetarium. (Details at http://www.philly.com/stellarstartups.)

A lot has to go right, all the planets and stars have to align for this to hit the market, Dishowitz said of PolyAurums commercial prospects.

Which is why the team behind any start-up is so essential to investors, he said, calling Travers interest in joining a company that has yet been unable to pay her (she has equity in PolyAurum) incredibly lucky.

Margo Reed

At the Nanomedicine and Molecular Imaging Lab at Penn Medicine are (front row, from left) Jay Dorsey, a radiation oncologist and a founder of PolyAurum; Debra Travers, CEO; and Andrew Tsourkas, another founder of PolyAurum; and (back row, from left) Michael Dishowitz, portfolio manager, PCI Ventures at Penn; and David Cormode, lab director and PolyAurum founder. (MARGO REED / Staff Photographer)

The only thing Travers corporate-heavy background lacked, he said, was raising money for a start-up. It doesnt worry him, Dishowitz said, citing Travers perseverance, no-quit attitude.

When youre out there raising money, youre going to hear no about 100, 150 times before you hear yes, Dishowitz said.

When it comes to pitching for PolyAurum, Travers has extra incentive.

I am working on a cancer therapeutic, which is very important to the 11-year cancer survivor in me, she said.

As for handling nos, shes had plenty of professional experience with that.

After spending 30-plus years in the drug and diagnostic industries, where it is hard to find women CEOs or board members, Travers said, Ive learned to ignore the negative voices.

When: 5:30-8:30 p.m. Tuesday, Sept. 12.

Where: Fels Planetarium, Franklin Institute, 222 N. 20th St., Philadelphia 19103

For more information: http://www.philly.com/stellarstartups

Published: July 28, 2017 3:01 AM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day. We’re thankful for your support in every way.

View post:

Cancer survivor becomes a cancer fighter at a Philly start-up – Philly.com

Nanomedicine and Extracellular Vesicles Lab – Kokomo Perspective

BOURBONNAIS, Ill. What is the biggest difference in the 2017 Chicago Bears since we left them at 3-13 last January?

Over the last six months, it has become crystal clear to anyone paying close attention the Chicago Bears are now general manager Ryan Paces team, while head coach John Fox just works there.

In the past two-and-a-half years, we can count on one hand the number of times Pace has spoken publicly without Fox by his side, and until last January it was always Fox who dominated those occasions, at times feeling the need to add to Paces comments and even finish answers for him.

Meeting with Pace and Fox Wednesday at the opening of the Bears’ 2017 training camp, it was clearly Ryan Paces show, completing the turnaround in control hes been asserting this offseason.

For anyone keeping score, after each gave a brief opening statement, the first 12 questions were all directed at Pace with Fox only weighing in on two of them because Pace asked him to, and many of them were about how Pace was handling the quarterback position, playing time and other decisions often left to the head coach.

Asked how he will measure the progress of this years Bears, Pace replied, I know that the culture and the vibe of the locker room is really good right now.

When we talk about playing with toughness and intelligence and passion and all those traits we strive for, I feel like weve got a team that embodies those traits.

Asked about the pressure on Fox to perform well enough to keep his job entering the third year of his four-year deal, Pace was careful to accept some of the pressure to win on himself while acknowledging it is time to win more, and he also offered a second measuring stick through which Fox will be evaluated.

I hear theres pressure on this theres pressure on all of us. Theres a lot of pressure on me, and we all know what we signed up for,” he said. “I think the focus now is winning games, but if theres one thing I can stress with John and things I appreciate every day its look, its very difficult to change a culture.

John is doing that and he has done that while also getting younger as a team. And doing that together has been difficult, and I appreciate that with him.

Asked how Fox is changing the culture, Pace explained, I think you guys know when you can feel a team that has come together, you can feel the locker room.

“Guys, this is just the very beginning, but you just feel a lot of good teammates. A lot of unselfish, team-first type of players, which I think is really important.

I think weve all seen good teams ascend, and I think it starts with the quality of the character in the locker room, and I think we have good character in our locker room.

How much pressure is on Fox to win now ultimately remains unclear, but Pace did acknowledge the ultimate judgments come from the McCaskeys ownership perch and he did talk about what he believes they expect.

That conversation is always ongoing. I just think they want to see continued improvement,” he said. “I think they know theres no quick fix. We talked about that. Its about building this team the right way, with the right kind of guys. And weve just got to show progress.

I think as we go forward, our fans are going to see a tough, blue collar, grind-it-out kind of team thats on the ascension and its something they can be part of.

I suspect Pace is right about how he will be evaluated and that he remains very safe in the eyes of the McCaskeys.

But while the culture may be improving, 2016 was a regression from six wins to three rather than progress, and whether Fox can expect that same leeway as Pace remains a serious question as practices begin Thursday.

See the rest here:

Nanomedicine and Extracellular Vesicles Lab – Kokomo Perspective

International Conference and Exhibition on Nanomedicine and Nanotechnology – Technology Networks

Short Name: Nanomed Meeting 2017

Theme: Challenges and Innovations in next generation medicine

Website: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology

Registration Link: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology/registration

Nanomed Meeting 2017 Organizing Committee invites you to attend the largest assemblage of Nanomedicine and Nanotechnology researchers from around the globe during November 23-24, 2017 at Dubai, UAE.

Nanomed Meeting 2017 is a global annual event. This International Conference and Exhibition on Nanomedicine and Nanotechnology brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of Nanomed Meeting 2017 through a decade at Asia finds much requirement for discussion also focusing the latest developments in the field of Nanomedicine and Nanotechnology.

Why attend?

Join your peers around the world focused on learning about Nanomedicine and Nanotechnology related advances, which is your single best opportunity to reach the largest assemblage of participants from the Nanomedicine and Nanotechnology community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Nanomedicine and Nanotechnology are hallmarks of this conference.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

The rest is here:

International Conference and Exhibition on Nanomedicine and Nanotechnology – Technology Networks

Global Nanomedicine Market 2017-2022 – Hoffmann-La Roche Ltd … – DailyHover

Worldwide Nanomedicine Market 2017 provides the in-depth research study shedding lights on different business verticals, key business factors which lead to market development, services offered by Nanomedicine industry. Worldwide Nanomedicine report is segmented into different categories based on the manufacturing regions to provide complete knowledge of Nanomedicine industry which will help them in making vital decisions. The opportunities, threats, and business strategies are covered in this report, forecast from 2016-2022.

Market Insights:

The consistent global demand for Nanomedicine provide positive growth opportunities for Nanomedicine market.The report identified that the global Nanomedicine market is driven by factors such as massive growth in Healthcare industry and commercial application in Healthcare industry. The growing demand from Healthcare industries are expected to drive the global Nanomedicine market. The growth in the Global Nanomedicine Market is likely to be restrained by factors such as High investment costs and longer duration of implementation.The global Nanomedicine market is expected to exhibit a CAGR of 17.1 % during the assessment period from 2016-2022.

Before purchasing the report please do inquire here: https://market.biz/report/global-nanomedicine-market-2017-ihr/103194/#inquiry

Initially, Worldwide Nanomedicine report provides basic industry overview to the reader. Then the key aspects of the Nanomedicine industry showing the growth of the market, product definitions, applications, Nanomedicine market scope on a global scale have been mentioned in this report. The research methods followed to gather all the Nanomedicine industry details has been included in this report.

The dominant Nanomedicine industry players are as follows:

1) Merck & Co.Inc. 2) Hoffmann-La Roche Ltd. 3) Gilead Sciences Inc. 4) Novartis AG 5) Amgen Inc. 6) Pfizer Inc. 7) Eli Lilly and Company 8) Sanofi 9) Nanobiotix SA 10) UCB SA

Worldwide Nanomedicine market than does the analysis of the dominant market players based on their company profiles, sales margin, customer volume, demand and supply ratio, business tricks followed by them. All the existing and emerging market segments of Nanomedicine market has been covered in this research report. The product price, market constraints, and evolving market regions have been included in this report.

The Geographical Analysis of Nanomedicine market:

1. Latin America (The Middle East and Africa)

2. Europe (UK, Germany, France, Italy, and Russia)

3. Asia-Pacific (India, China, Korea, Japan and Southeast Asia)

4. North America (The USA, Canada, and Mexico)

The SWOT analysis of the Nanomedicine market, business trends, geographic revenue, business sections has been included in this report.

Towards the end, important research findings, product releases, collaborations have been incorporated in Nanomedicine research report.

More here:

Global Nanomedicine Market 2017-2022 – Hoffmann-La Roche Ltd … – DailyHover

Tiny robots swim the front crawl through your veins – New Scientist

Michael Phelps: Faster than a nano-swimmer but wont fit in your veins

Francois Xavier Marit/AFP/Getty Images

By Leah Crane

Its no Michael Phelps, but this tiny magnetic robot swims the front crawl at 10 micrometres per second. It would take about two months for the bot to swim the length of an Olympic swimming pool in that time, Phelps could swim almost 5 million lengths. But the nano-swimmer is fast for its size, and its strong enough to pass through more viscous liquids, like blood, to deliver medicine from inside your veins.

The front crawl is the fastest way for humans to swim. So Tianlong Li at the Harbin Institute of Technology in China and his colleagues built their swimming robot to mimic that motion.

Each nano-swimmer is 5 micrometres long and has three main parts, connected together like sausage links by two silver hinges. Its gold body is flanked by two magnetic arms made of nickel, and applying a magnetic field to the tiny robot makes the arms move.

As the researchers switch the magnetic fields direction back and forth, it causes the arms of the nano-swimmer to rotate and propel it forward, just like the arms of a human swimmer doing the front crawl.

Its exciting due to its speed and its really small size, just about the same size as a blood vessel, says Eric Diller at the University of Toronto in Canada who researches micro-robots. Its small enough basically to go anywhere within the body.

Because bodily fluids are more viscous and difficult to swim through than water, the researchers also tested their nano-swimmers in serum. The bots were only able to swim 5.5 micrometres per second, but thats still faster than many other similar mini-machines.

For targeted medicine delivery without invasive procedures, these nano-swimmers could be coated with medicine and injected into the bloodstream, where their trajectories could be roughly steered by external magnetic fields.

Since they are so small, just one nano-swimmer wouldnt be able to carry enough medicine to actually help. Maybe a thousand of them would be necessary, says Diller. Theres no way to keep track of all of them, so there are a lot of questions about safety and toxicity.

The next generation of these tiny machines will have to be made from biodegradable materials before they can be used in the bloodstream. But, Diller says that for less complicated areas in the human body like the urinary tract or the eyeballs, clinical trials could begin within the next five to 10 years. Injecting a single swimmer into an eyeball, where it could deliver medication directly to the retina and then be removed, would be much less complicated than letting a swarm of them swim throughout the entire circulatory system.

We dont know how fast Michael Phelps could swim through blood thankfully, his recent race against a great white shark didnt provide a testing ground. But since you cant inject him into your bloodstream, these nano-swimmers will have to do.

Journal reference: Nano Letters, DOI: 10.1021/acs.nanolett.7b02383

Read more: DNA origami nanorobot takes drug direct to cancer cell

More on these topics:

Read more:

Tiny robots swim the front crawl through your veins – New Scientist

Chennai firm to produce ayurvedic drugs for cancer thru nanotech – Hindu Business Line

Chennai, July 21:

Chennai-based Dhanvantari Nano Ayushadi Pvt Ltd will produce nano ayurvedic medicine to treat cancer using green nanotechnology. The products are expected to hit the shelves in early 2018 after clinical trial.

Green nanotechnology uses herbs and spices such as cinnamon, tea or soyabean to synthesise gold nanoparticles. The activated gold nano particles are then used to make capsules and tablets that can be consumed. The technology is developed by Kattesh V Katti, Director, Institute of Green Nanotechnology, Medical School, University of Missouri in the US.

Addressing the media today, S Abhaya Kumar, Chairman, Nano Ayushadi, said clinical trials will start from August 1 under the guidelines issued by the Union Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH). Trials will be conducted over a period of 3-6 months on 100 people selected through random sampling. The company has invested 60 crore to license the technology, manufacturing unit and clinical trial. With scientific backing, we expect to sell close to 20 million capsules initially, he added. In the next five years, we expect to be a 1,000-crore company, he added.

The company is in talks with cancer institutes, hospitals and doctors to reach a wider audience. Kumar said products would be available through Ayurveda distributors and e-commerce platforms.

Talking about the effectiveness of the product, Katti , said that from the trials conducted on over 100 animals over a period of four years, nano ayurvedic medicine is found to reduce the tumour without side effects. When the medicine is taken alongside chemotherapy, it has shown to be effective, he added.

(This article was published on July 21, 2017)

Please enter your email. Thank You.

Newsletter has been successfully subscribed.

Link:

Chennai firm to produce ayurvedic drugs for cancer thru nanotech – Hindu Business Line


12345...1020...